iA Global Asset Management Inc. Buys Shares of 1,647 Alnylam Pharmaceuticals, Inc. $ALNY

iA Global Asset Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,647 shares of the biopharmaceutical company’s stock, valued at approximately $751,000.

Other large investors also recently modified their holdings of the company. Rakuten Investment Management Inc. bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $14,205,000. Chicago Partners Investment Group LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $463,000. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $211,000. Dynasty Wealth Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $305,000. Finally, Jackson Thornton Wealth Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $414,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 3.2%

ALNY stock opened at $357.98 on Friday. The company has a market capitalization of $47.29 billion, a PE ratio of 1,491.58 and a beta of 0.32. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company’s 50 day moving average price is $409.91 and its two-hundred day moving average price is $423.26.

Analyst Ratings Changes

ALNY has been the subject of several recent analyst reports. Jefferies Financial Group reduced their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Royal Bank Of Canada cut their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Truist Financial lowered their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Leerink Partners dropped their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Finally, Bank of America cut their price target on shares of Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating for the company in a research note on Monday, January 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $485.21.

Insider Buying and Selling

In other news, EVP Jeffrey V. Poulton sold 2,780 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Pushkal Garg sold 1,510 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the sale, the executive vice president directly owned 22,511 shares of the company’s stock, valued at approximately $8,168,566.57. This trade represents a 6.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 56,955 shares of company stock worth $24,072,733 over the last 90 days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.